{
  "ticker": "AGN",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971713",
  "id": "02971713",
  "pages": 10,
  "price_sensitive": true,
  "date": "20250723",
  "time": "0842",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m1mqm97m56my.pdf",
  "summary": "**Appendix 4C Quarterly Report Summary (Argenica Therapeutics, ASX: AGN, 30 June 2025):**  \n\n- **Key Operational Highlights:**  \n  - Phase 2 trial for ARG-007 in acute ischaemic stroke (AIS) completed final patient dosing (April 2025); topline data expected Q3 2025.  \n  - Positive preclinical results in traumatic brain injury (TBI), supporting further clinical development.  \n  - FDA placed clinical hold on US IND application for ARG-007 (no impact on Australian Phase 2 trial).  \n  - New US patent granted for neuroprotective peptides in surgical stroke prevention (expiry 2034).  \n\n- **Financial Highlights:**  \n  - **Cash balance:** $10.5M (as at 30 June 2025), sufficient to fund Phase 2 trial results release.  \n  - Quarterly net operating cash outflow: $2.36M (R&D spend: $2.1M).  \n  - Received $1.5M non-dilutive MRFF grant ($243K initial tranche post-quarter).  \n\n- **Catalysts:**  \n  - Phase 2 topline data (Q3 2025) and pending FDA IND resolution critical near-term valuation drivers.  \n\n*Omitted: Routine grant details, director payments, and non-material operational updates.*",
  "usage": {
    "prompt_tokens": 6270,
    "completion_tokens": 284,
    "total_tokens": 6554,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T23:00:00.387089"
}